Biopharmaceutical News and Research

RSS

MGI PHARMA acquires Aesgen for $32 million

MGI PHARMA today announced that they have signed a definitive merger agreement under which MGI PHARMA will acquire all outstanding equity of Aesgen for $32 million in cash.

1 Sep 2004

Kiwis reverse heart disease in diabetics

New Zealand biopharmaceutical company Protemix Corporation has announced the discovery of a treatment which appears to reverse heart disease in people suffering from diabetes and may lead to a more effective intervention in a major cause of death worldwide.

30 Aug 2004

Development of plant-derived topical medications to prevent HIV/AIDS and other STD's

Researchers at the Biodesign Institute at ASU have been tapped to lead development of plant-derived topical medications that would prevent HIV/AIDS and other sexually-transmitted diseases.

21 Aug 2004

IBM and Cellomics offer new solution to accelerate cell-based drug discovery

IBM and Cellomics have announced they have launched a customized information technology (IT) solution that allows biopharmaceutical scientists and academic researchers to better understand how potential drug candidates or targets of interest affect cellular function.

11 Aug 2004

Patent pending botanical extract, V38-AMF-1, completely inhibits bird flu (H5N1) and Fujian Flu

PRB Pharmaceuticals and Lee's Pharmaceuticals have announced the discovery that PRB'S patent pending botanical extract, V38-AMF-1, completely inhibits bird flu (H5N1) and Fujian Flu (H3N2) infections in vitro.

29 Jul 2004

Y's Therapeutics files for clinical trials in Europe for rheumatoid arthritis and asthma

Y's Therapeutics, a privately held biopharmaceutical company, said today it has submitted applications to the Ethics Committee and Ministry of Health (BfArM) in Germany to begin Phase II clinical trials for its two most advanced projects, YSIL6 for rheumatoid arthritis and YSTH2 for asthma.

26 Jul 2004

Emerging nanomedicine technologies could dramatically transform medical science

Emerging nanomedicine technologies could dramatically transform medical science as we know it today with their potential to address unmet medical needs and provide targeted therapy.

23 Jul 2004

Neuro3d identifies candidate compound

The identification of this compound and extension of the research collaboration by J&JPRD further highlights the strength of Neuro3d's internal drug discovery capabilities.

21 Jul 2004

Outsourcing the way to control spiraling R&D budgets in drug industry

Companies developing new drugs for the global market must deal with the rising costs of the R&D process – and outsourcing may well be the best route. That's the verdict of Dr Faiz Kermani, a specialist in outsourcing and research development for the pharmaceutical industry.

14 Jun 2004

Autodesk engineering solution addresses healthcare design challenges

Autodesk, Inc., a leading design software and digital content company, has announced that engineering firms are increasingly using Autodesk(R) Building Systems to create, manage and share critical building design information for healthcare, biomedical research and biopharmaceutical projects.

31 May 2004

Research tests the efficacy of a smallpox vaccine candidate known as LC16m8

When used as an aerosolized weapon, smallpox could be controlled by a new vaccine under study at Saint Louis University School of Medicine, according to new data.

27 May 2004

Genetically engineered viruses may create new class of cancer therapies

A genetically engineered virus can selectively kill cancerous cells in the lung and colon while leaving healthy cells intact, according to new research published today in Cancer Research by William Wold and colleagues at Saint Louis University School of Medicine.

15 May 2004

Biochip technology to revolutionise the pharmaceutical industry

Advancements in biotechnology have culminated in its integration with semiconductor technologies such as micro-electromechanical systems, resulting in the evolution of biochips. Biochips provide pharma companies with sophisticated tools for speedy development of drugs and accurate diagnosis and understanding of biological mechanisms.

13 May 2004

IBM introduces new BioPharmaceutical solution

IBM today announced a new fixed-price offering for small and mid-sized businesses (SMBs) navigating government compliance mandates for the United States pharmaceutical industry.

13 May 2004

Ingenium's acquisition of US patents may lead to drug discovery and development

Ingenium Pharmaceuticals AG has acquired outright US patents no. 5,994,075 and no. 6,015,670 from Incyte Corporation, the company announced today.

12 May 2004

$FDA approves INFUSE® bone graft which improves fracture healing$

FDA approves INFUSE® bone graft which improves fracture healing

Medtronic, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved the use of INFUSE® Bone Graft in the treatment of acute, open fractures of the tibial shaft, a long bone in the lower leg. The approval broadens the indications for INFUSE Bone Graft, a product that has been used since 2002 in spinal surgery with metallic cages to treat tens of thousands of patients.

4 May 2004

Wyeth gets FDA approval for a novel protein device that enhances bone healing

Wyeth have announced that the FDA has approved rhBMP-2/ACS (recombinant human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge), a novel protein device that enhances bone healing, for use in the treatment of acute, open tibia shaft fractures in adults.

3 May 2004

Carbohydrate-binding proteins are becoming extremely useful in curing various illnesses

Researchers are beginning to see the potential for breakthrough in healthcare through glycomics, which studies carbohydrates, proteins and their interactions. In fact, these carbohydrates are moving beyond their regular roles as sugar storage bins.

28 Apr 2004

AGT Biosciences Limited and ChemGenex Therapeutics today announced merger agreement

AGT Biosciences Limited of Melbourne, Australia and privately held ChemGenex Therapeutics, Inc. of Menlo Park, California, today announced that they have signed a merger agreement. The cross-border merger creates a new, genomics-driven pharmaceutical company with leading edge capabilities for drug discovery and development, as well as two drug candidates in Phase II human trials for cancer.